Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NMS 03592088

Next Previous
Drug Profile

NMS 03592088

Alternative Names: NMS-03592088; NMS-088; NMS-P088

Latest Information Update: 12 Jan 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nerviano Medical Sciences
  • Class Antineoplastics
  • Mechanism of Action Fms-like tyrosine kinase 3 inhibitors; Macrophage colony-stimulating factor receptor antagonists; Proto-oncogene protein c-kit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Acute myeloid leukaemia; Chronic myelomonocytic leukaemia

Most Recent Events

  • 09 Jan 2024 Phase-I/II clinical trials in Acute myeloid leukaemia (Monotherapy) in Europe, USA (PO)
  • 09 Jan 2024 NMS 03592088 receives Orphan Drug status for Acute myeloid leukaemia in USA
  • 22 Jun 2023 The US FDA approves IND application for NMS 03592088 in Acute myeloid leukaemia (Second-line therapy or greater)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top